Clinical trial
Safety/Tolerance Study of PPI-2458 in Subjects With Non-Hodgkin's Lymphoma and…
NCT00100347 · PRAECIS Pharmaceuticals Inc., Industry · Terminated
Key facts
| NCT number | NCT00100347 |
|---|---|
| Title | Safety/Tolerance Study of PPI-2458 in Subjects With Non-Hodgkin's Lymphoma and Solid Tumors |
| Official title | A Phase 1 Dose Escalation Safety/Tolerance Study of PPI-2458 in Subjects With Non-Hodgkin's Lymphoma and Solid Tumors |
| Lead sponsor | PRAECIS Pharmaceuticals Inc., Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma, Solid Tumors |
| Intervention type | Drug |
| Interventions | PPI-2458 |
| Enrollment | 45 |
| Start date | Dec 1, 2004 |
| Completion | Jul 1, 2007 |
| First posted | Dec 30, 2004 |
| Last update posted | Jul 25, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: